Scholarlink

Background and objectives <p>Repeat transurethral resection of bladder tumor (2nd -TURBT) is recommended for high-risk non-muscle invasive bladder cancer (HR-NMIBC) to reduce the risk of understaging and residual tumors. Despite its proven benefits, 2nd -TURBT remains an invasive and costly procedure. This study aimed to evaluate if bladder MRI, performed before initial TURBT (i-TURBT), could be in selected patient, a non-invasive alternative to 2nd -TURBT.</p> Methods <p>Data from 34 single-center patients who had MRI performed prior to i-TURBT and underwent 2nd -TURBT for HR-NMIBC between March 2020 and July 2024 were retrospectively collected.</p> Results <p>MpMRI demonstrated high accuracy in detecting muscle-invasive bladder cancer, with sensitivity, specificity, positive predictive value, and negative predictive value of 100% (95% CI 0.61-1), 96% (95% CI 0.82–0.99), 86% (95% CI 0.49–0.97), and 100% (95% CI 0.87-1), respectively. Among patients with mpMRI findings suggestive of NMIBC (<i>n</i> = 27), the residual tumor rate was 12% (<i>n</i> = 3). No residual tumor was found on 2nd-TURBT in patients with pTa tumor (<i>n</i> = 6) on i-TURBT and VIRADS ≤ 3, neither with pT1 tumor and detrusor muscle sampled on i-TURBT (<i>n</i> = 28), with unifocal VIRADS ≤ 3.</p> Conclusion <p>Bladder MRI appears to be a valuable tool in HR-NMIBC management and could avoid 2nd -TURBT in selected patients, with a unifocal VIRADS ≤ 3 lesion and detrusor muscle sampled in i-TURBT.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Can bladder MRI avoid systematic second TURBT for patients with high-risk NMIBC?

  • 期刊论文

  • 发表日期：

    2025年10月15日

查看全文
  • Louis Gobinet,
  • Clément Klein,
  • Serge Brunelle,
  • Mathias Illy,
  • Gwenaelle Gravis,
  • Jochen Walz,
  • Nicolas Branger,
  • Geraldine Pignot

摘要

Background and objectives

Repeat transurethral resection of bladder tumor (2nd -TURBT) is recommended for high-risk non-muscle invasive bladder cancer (HR-NMIBC) to reduce the risk of understaging and residual tumors. Despite its proven benefits, 2nd -TURBT remains an invasive and costly procedure. This study aimed to evaluate if bladder MRI, performed before initial TURBT (i-TURBT), could be in selected patient, a non-invasive alternative to 2nd -TURBT.

Methods

Data from 34 single-center patients who had MRI performed prior to i-TURBT and underwent 2nd -TURBT for HR-NMIBC between March 2020 and July 2024 were retrospectively collected.

Results

MpMRI demonstrated high accuracy in detecting muscle-invasive bladder cancer, with sensitivity, specificity, positive predictive value, and negative predictive value of 100% (95% CI 0.61-1), 96% (95% CI 0.82–0.99), 86% (95% CI 0.49–0.97), and 100% (95% CI 0.87-1), respectively. Among patients with mpMRI findings suggestive of NMIBC (n = 27), the residual tumor rate was 12% (n = 3). No residual tumor was found on 2nd-TURBT in patients with pTa tumor (n = 6) on i-TURBT and VIRADS ≤ 3, neither with pT1 tumor and detrusor muscle sampled on i-TURBT (n = 28), with unifocal VIRADS ≤ 3.

Conclusion

Bladder MRI appears to be a valuable tool in HR-NMIBC management and could avoid 2nd -TURBT in selected patients, with a unifocal VIRADS ≤ 3 lesion and detrusor muscle sampled in i-TURBT.